Comments
MSN Laboratories has launched the generic Canrealtm injection (Cangrelor) in the domestic market with due approval from the Drug Controller General of India.
It is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularisation, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor, the Hyderabad-based company said in release.
The product, which comes in a single-use 10 mL vial containing 50 mg Cangrelor as a lyophilized powder for reconstitution, is manufactured at US and EU approved state-of-the-art injectable facility in Hyderabad, it added.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.